"I am unable to fully participate in the board work as I would like due to my current workload. Therefore, I have chosen to end my assignment, creating an opportunity for someone who can wholeheartedly dedicate themselves to GA's future development," Staffan Strömberg, board member of GA, explained.

"It is sad to have to leave the GA board because I believe that the company is on the threshold of establishing increased sales through the new distribution network that the management of the company has established. I am the CEO of a Swedish company that has begun preparations for a global launch of a new pharmaceutical drug. The launch preparations take up my focus and I have therefore decided to leave two board assignments, of which GA is one," explained Staffan Strömberg, board member of GA.

"We have great respect for Staffan Strömberg's decision and on behalf of the Board I thank him for his valuable contribution to the work of the Board and wish all the best for the future," comments Per Matsson, chairperson of Genetic Analysis.

According to GA's articles of association, the BoD shall consist of a minimum of two and a maximum of seven members. When Staffan Strömberg has resigned, the BoD will consist of four members, thus fulfilling the requirements of the articles of association.

For more information, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com